Tailored gene expression in practice
Discover how therapy, biomanufacturing and crop developers use Annogen’s platforms to turn complex gene expression challenges into validated, actionable solutions.
Discuss your challenge
Research collaboration
Orchard Therapeutics
VectorY’s VTx-002
ALS clinical trials phase 1&2
T-cell therapies
T-cell-specific and activation-inducible promoters, now in the hands of more than a dozen biopharma. Off-the-shelf, validated, and licensable, so teams skip months of in-house promoter work.
Biomanufacturing
A CHO expression vector that lifts titer up to 3-fold over standard CMV. Screened directly in the relevant CHO context, validated before hand-off, compatible with random and PiggyBac integration.
Integration sites
Mapping more than 100,000 genomic loci in T-cells to find where a transgene expresses inducibly on T-cell activation. AIM™ turns integration-site choice from assumption into measured evidence.
